<DOC>
	<DOCNO>NCT00400400</DOCNO>
	<brief_summary>Treatment immunosuppressive drug mycophenolate mofetil ( MMF ) may result gastrointestinal ( GI ) complication patient . This study investigate safety tolerability convert kidney transplant recipient gastrointestinal symptom current treatment mycophenolate mofetil ( MMF ) treatment enteric-coated mycophenolate sodium ( EC-MPS ) .</brief_summary>
	<brief_title>Enteric-coated Mycophenolate Sodium ( EC-MPS ) Mycophenolate Mofetil ( MMF ) Renal Transplant Patients With Gastrointestinal ( GI ) Intolerance</brief_title>
	<detailed_description />
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criterion : Males female age 1875 year , Recipients first second cadaveric , live unrelated living relate kidney transplant Recipients least 4 week post renal transplantation stable renal function , Patients currently receive MMF ( dosage allow ) either cyclosporine USP ( MODIFIED ) tacrolimus without corticosteroid part immunosuppressive regimen least 2 week prior study start Patients least one mild and/or moderate and/or severe upper low gastrointestinal ( GI ) complaints clearly associate MMF therapy determine treat physician . Additional mild GI complaint may coexist Patients ' immunosuppressive regimen steroid ( dos type ) well medication treatment GI symptom must unchanged least 1 week prior study start Females childbearing potential must negative pregnancy test prior inclusion period . The test perform locally Baseline visit . If positive , patient include . Effective contraception must use trial , 4 week follow discontinuation study medication Patients willing able participate full course study write informed consent obtain . Exclusion criterion : Multiorgan transplant patient ( e.g . kidney pancreas ) previous transplant organ different kidney ( second kidney transplant allow ) History GI disorder ( diarrhea , Gastroesophageal Reflux Disease ( GERD ) , dyspepsia , Inflammatory Bowel Disease ( IBD ) Irritable Bowel Syndrome ( IBS ) prior transplantation Evidence GI disorder induce infection , underlie medical condition , concomitant medication MMF , Modification GI medication MMF dose within last 1 week Evidence graft rejection , treatment acute rejection , unstable renal function within 4 week prior Baseline visit , Patients receive investigational immunosuppressive drug within 4 week prior study entry Patients history malignancy within last five year , except excise squamous basal cell carcinoma skin Pregnant nursing ( lactate ) woman , Women childbearing potential ( WOCBP ) use acceptable method contraception : surgical sterilization , hormonal contraception , doublebarrier method . Contraception maintain throughout study 4 week study drug discontinuation . Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>RenalTransplantation</keyword>
	<keyword>KidneyTransplantation</keyword>
	<keyword>MPA</keyword>
	<keyword>EC-MPS</keyword>
</DOC>